Anti-VEGF therapy did not maintain visual acuity gains in AMD patients at 5 years

SEATTLE — Patients with neovascular age-related macular degeneration who were treated with anti-VEGF therapy did not maintain visual gains at 5 years, according to the Comparison of Age-Related Macular Degeneration Treatment Trials results presented here. “Our primary goal of the CATT follow-up study was to assess the overall visual acuity and morphologic outcomes at 5 years of any anti-VEGF treatment,” Daniel F. Martin, MD, said at the Association for Research in Vision and Ophthalmology meeting.

Full Story →